These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 28106066)

  • 1. The psychosis spectrum in Parkinson disease.
    Ffytche DH; Creese B; Politis M; Chaudhuri KR; Weintraub D; Ballard C; Aarsland D
    Nat Rev Neurol; 2017 Feb; 13(2):81-95. PubMed ID: 28106066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychosis in Parkinson's Disease.
    Ffytche DH; Aarsland D
    Int Rev Neurobiol; 2017; 133():585-622. PubMed ID: 28802934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hallucinations and psychosis in Parkinson's disease.
    Rabey JM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative.
    Ffytche DH; Pereira JB; Ballard C; Chaudhuri KR; Weintraub D; Aarsland D
    J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):325-331. PubMed ID: 28315846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia.
    Barrett MJ; Smolkin ME; Flanigan JL; Shah BB; Harrison MB; Sperling SA
    Parkinsonism Relat Disord; 2017 Oct; 43():56-60. PubMed ID: 28735797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
    Zahodne LB; Fernandez HH
    Drugs Aging; 2008; 25(8):665-82. PubMed ID: 18665659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.
    Rojas M; Chávez-Castillo M; Duran P; Ortega Á; Bautista-Sandoval MJ; Salazar J; Riaño-Garzón M; Chacín M; Medina-Ortiz O; Palmar J; Cudris-Torres L; Bermúdez V
    Curr Pharm Des; 2022; 28(33):2725-2741. PubMed ID: 36321314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosis in Parkinson's disease.
    Thanvi BR; Lo TC; Harsh DP
    Postgrad Med J; 2005 Oct; 81(960):644-6. PubMed ID: 16210460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of psychotic symptoms in a community-based Parkinson disease sample.
    Mack J; Rabins P; Anderson K; Goldstein S; Grill S; Hirsch ES; Lehmann S; Little JT; Margolis RL; Palanci J; Pontone G; Weiss H; Williams JR; Marsh L
    Am J Geriatr Psychiatry; 2012 Feb; 20(2):123-32. PubMed ID: 21617521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease psychosis: presentation, diagnosis and management.
    Schneider RB; Iourinets J; Richard IH
    Neurodegener Dis Manag; 2017 Dec; 7(6):365-376. PubMed ID: 29160144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson disease psychosis: from phenomenology to neurobiological mechanisms.
    Pagonabarraga J; Bejr-Kasem H; Martinez-Horta S; Kulisevsky J
    Nat Rev Neurol; 2024 Mar; 20(3):135-150. PubMed ID: 38225264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series.
    Rothenberg KG; McRae SG; Dominguez-Colman LM; Shutes-David A; Tsuang DW
    Am J Case Rep; 2023 Sep; 24():e939806. PubMed ID: 37775968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.
    Aarsland D; Larsen JP; Cummins JL; Laake K
    Arch Neurol; 1999 May; 56(5):595-601. PubMed ID: 10328255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
    Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
    J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
    [No Abstract]   [Full Text] [Related]  

  • 16. Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis.
    Kulick CV; Montgomery KM; Nirenberg MJ
    Parkinsonism Relat Disord; 2018 Sep; 54():40-45. PubMed ID: 29653909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
    Sellers J; Darby RR; Farooque A; Claassen DO
    Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms.
    Lee AH; Weintraub D
    Mov Disord; 2012 Jun; 27(7):858-63. PubMed ID: 22674352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
    Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
    J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.